Abstract:Objective To control the quality ofFici Hirtae Radix by establishing quality standards.Methods The origin mistakes of Fici Hirtae Radix in Chinese Pharmacopoeia (1977 edition) were modified by searching and mining plant morphology characters,distribution of origin,historical evolution,clinical efficacy and modem research,medicinal standards in different regions on Ficus hirta Vahl and Ficus simplicissima.Morphological identification,microscopical characteristics based on transverse section and powder,and thin layer chromatography were adopted to identify commercial medicinal materials ofFici Hirtae Radix from different sources.The content of psoralen and bergapten was determined by HPLC.Moisture content,total ash,acid-insoluble ash,and ethanol-soluble extractives were determined by methods described in appendices of Chinese Pharmacopoeia (2010 edition).Results The origin of Fici Hirtae Radix was not F.simplicissima Lour.,but F.hirta Vahl.This study collected 20 Fici Hirtae Radix commercial medicines mixed 40％ non-medicinal parts samples.TLC data,morphological characteristics and microscopic characteristics,both showed obvious distinction.The concentration ofpsoralen and bergapten showed the content ofpsoralen range from 0.008 48％ to 0.150％,and the content of bergapten range from 0.005 87％ to 0.026 3％,and the contents of two index components ofFici Hirtae Radix were significantly higher than the non-medicinal parts samples.The moisture content ranged from 4.73％ to 8.27％,total ash ranged for 2.58％ to 4.37％,acid insoluble ash ranged for 0.054％ to 0.710％,ethanol-soluble extracts ranged for 6.23％ to 8.34％.Conclusion This paper revised the origin error ofFici Hirtae Radix of Chinese Pharmacopoeia (1977 edition) that its specification medicinal part should be the roots ofF.hirta,and established quality standards ofFici Hirtae Radix,and these methods could comprehensively and effectively control the quality of commercial medicinal materials ofFici Hirtae Radix.This study could provide evidence for rational,safe,and effective clinical application ofFici Hirtae Radix.

Quality analysis of Fufang Huangliansu Tablets

Quality analysis of Lingyang Ganmao Tablets

Study on quality standards for Lingmaoxiang Jiedu pills

Assay of salvianolic acid B in compound Fufang Danshen Tablets in different manufacturers

Study on Revised Quality Standards of Fukangning Tablets

Study on quality standard of Yiqihuoxue Tablets

Study on Quality Standard for Fengshi Antai Tablets

Research on Dissolution Profiles of Compound Huangliansu Tablets from Different Manufacturers

Development of a method using high-performance liquid chromatographic fingerprint and multi-ingredients quantitative analysis for the quality control of Yangxinshi Pian.

New Quality Evaluation of Qizhi Xiangfu Pills Based on Fingerprint with Chemometric Analysis and Quantitative Analysis of Multi-Components by Single Marker

Study on Quality Standard of Shuangbai Tablets

Quality Control of Liujun Shengfa Tablets

Improvement of the Quality Standard for Suxiao Niuhuang Pills

Comprehensive Quantitative Analysis of 32 Chemical Ingredients of a Chinese Patented Drug Sanhuang Tablet

Study on the quality standard of Yangxinkaiyu Tablets

Quality Standard of Agui Yangxue Tablets

Study on quality standard of Fici Hirtae Radix

Study on the quality standard of Huayu Sanjie Tablets

Rapid and comprehensive quality evaluation of Huang‐qin from different origins by FT‐IR and NIR spectroscopy combined with chemometrics

Quality Diversity Analysis of Radix Astragali from Different Habitats

Development of a novel method combining HPLC fingerprint and multi-ingredients quantitative analysis for quality evaluation of traditional Chinese medicine preparation.